DTC rift as Bristol ban breaks ranks

By Published on .

Bristol-Myers Squibb's move to self-impose a year long ban on DTC ads creates a major rift in the pharmaceutical marketing world.

Officially, most of Bristol-Myers' rivals declined to comment on the company's decision to voluntarily abandon DTC ads during a product's first year on the market and to limit the times of day when it advertises drugs on TV. But unofficially most are in stark disagreement with Bristol-Myers' position.

One rival even remarked that beleaguered Bristol- Myers, which has only just settled a federal charge of accounting impropriety, can do this as it has little to lose. "They've got a great pipeline," commented the executive, "but hardly any of it is conducive to a big DTC campaign."

The industry's top lobby group, the Pharmaceutical Research and Manufacturers of America, also disagrees with its member's stance. A spokesman for the group, which is about a month away from releasing its own code of conduct for the $3.8 billion DTC category, and is trying to head off the looming horror of congressional regulation, said patients "have a right to know about new drugs." Executives familiar with some of the wording in the drafts say that a moratorium of any length is not part of the guidelines.

When Advertising Age recently editorialized that such a moratorium would be a positive move, almost every group involved in pharmaceutical advertising or marketing-including the Association of National Advertisers and the American Association of Advertising Agencies-railed against the notion. They said such a move would be "anti-consumer," and pointed out that an FDA survey found 89% of doctors believe DTC advertising made patients more involved in their health care.

But Bristol-Myers CEO Peter Dolan is set to take over as PhRMA's chairman next year, replacing current chair William Weldon, the CEO of Johnson & Johnson. Mr. Weldon, in fact, may be the closest thing Bristol-Myers has to an ally in this debate. Earlier this year he said Johnson & Johnson would be changing its DTC ads to reflect more risk information and challenged the industry to do the same. Mr. Weldon's remarks were said by some to be a "public relations ploy."


The Bristol-Myers move comes as members of Congress have focused their attention on DTC advertising. One bill, from Sen. Charles Grassley, R-Iowa, chairman of the Senate Finance Committee, and Sen. Chris Dodd, D-Conn., would require ads for newly approved drugs to carry extensive new warning labels.

But the industry as a whole has been under fire from the public since late last year, when the prescription anti-inflammatory drug Vioxx was pulled from the market, followed by the Food and Drug Administration's request that Pfizer pull its ads for Celebrex, a similar drug.

Most of Bristol-Myers' drugs that are close to FDA approval are therapeutic, including medications for cancer. Moreover, Bristol-Myers has been at the bottom end of the spending chart when it comes to measured media. The company spent $171 million last year according to TNS Media Intelligence. By comparison, Pfizer spent $1 billion, GlaxoSmithKline spent $861 million, Novartis $560 million and Merck $412 million.

The move also comes with curious timing on another level. On June 15, the company agreed to pay $300 million in a deal to defer federal prosecution of a conspiracy charge that stems from an accounting scandal. The U.S. Attorney's office in New Jersey said the investigation is ongoing and that more charges are possible.

Most Popular
In this article: